Insider Trading May 4, 2026 03:34 PM

Standex International Director Executes Scheduled Stock Sale Amid Recent Earnings Miss

Thomas Chorman disposes of 50 shares under a pre-arranged 10b5-1 plan as SXI faces valuation scrutiny and recent revenue shortfalls.

By Derek Hwang SXI
Standex International Director Executes Scheduled Stock Sale Amid Recent Earnings Miss
SXI

Thomas E. Chorman, a director at Standex International Corp. (NASDAQ:SXI), completed a sale of common stock on May 1, 2026. The transaction involved the sale of 50 shares at a price point of $268.43 per share, totaling a value of $13,421. This specific disposal was conducted in accordance with an existing 10b5-1 trading plan that had been established on November 6, 2025.Following the execution of this trade, Mr. Chorman maintains a direct holding of 12,516 shares of Standex International common stock. This insider activity occurs during a period where SXI shares have experienced volatility, trading at approximately $248.80, which represents a decline of roughly 8% over the previous week. Despite this recent downward movement in share price, the company maintains a market capitalization of $3.02 billion.

Key Points

  • Director Thomas Chorman sold 50 shares at $268.43 per share via a pre-existing 10b5-1 plan.
  • Standex International reported fiscal Q3 2026 revenue of $224.6 million and EPS of $2.21, both slightly missing forecasts.
  • The company showed an 8.1% year-over-year revenue growth despite the recent quarterly miss.

Standex International Corp. (NASDAQ:SXI) recently saw insider activity from one of its directors. On May 1, 2026, Thomas E. Chorman executed a sale of 50 shares of common stock at a price of $268.43 per share. This transaction resulted in a total sale value of $13,421 and was carried out under the framework of a 10b5-1 trading plan originally set up on November 6, 2025.

Post-transaction, Mr. Chorman's direct ownership in the company stands at 12,516 shares. The timing of this sale coincides with a recent dip in the market value of SXI, which has fallen approximately 8% over the last seven days to a trading level of $248.80. Standex International continues to hold a significant market presence with a market capitalization of $3.02 billion.


Key Transactional and Financial Points

The recent activity at Standex International highlights several critical data points regarding the company's current financial standing:

  • Scheduled Insider Disposition: The sale by Director Thomas Chorman was not an unscheduled market event but was executed through a 10b5-1 plan established in late 2025.
  • Earnings Performance: In its fiscal third-quarter 2026 earnings report, Standex International reported results that fell slightly short of analyst expectations. The company posted earnings per share (EPS) of $2.21, missing the forecasted $2.23. Additionally, revenue reached $224.6 million, trailing the anticipated $225.76 million.
  • Growth and Stability: Despite the recent misses in EPS and revenue, the company demonstrated an 8.1% increase in total revenue on a year-over-year basis. Furthermore, Standex has demonstrated long-term dividend consistency, having maintained payments for 56 consecutive years.

These factors influence the industrial and specialty chemical sectors where Standex operates, as internal performance metrics and dividend reliability are key indicators for market stability.


Risks and Market Uncertainties

Several uncertainties remain for investors monitoring Standex International:

  • Valuation Discrepancies: Analysis suggests that SXI may currently be overvalued relative to its estimated Fair Value, presenting a risk for those entering positions at current price levels.
  • Revenue and Earnings Volatility: The recent inability to meet specific EPS and revenue targets indicates potential short-term headwinds in meeting market expectations.
  • Stock Price Momentum: With the stock trading down roughly 8% over a one-week period, the immediate price trend reflects recent downward pressure on the equity.

These uncertainties impact the broader equity markets by highlighting the gap between historical dividend reliability and current earnings execution.

Risks

  • Potential overvaluation of SXI stock relative to its Fair Value.
  • Recent downward price pressure with an 8% weekly decline in share value.
  • Shortfall in meeting projected EPS and revenue targets in the latest fiscal quarter.

More from Insider Trading

Emergent BioSolutions Director Keith Katkin Executes Stock Sales and Receives New Equity Grants May 4, 2026 Emergent BioSolutions Director Executes Stock Sales Under Pre-Arranged Plan May 4, 2026 Emergent BioSolutions Director Executes Stock Sale Under Rule 10b5-1 Plan May 4, 2026 Westwood Holdings Group Emerita Director Executes Scheduled Stock Sales May 4, 2026 I Squared Capital-Linked Entities Liquidate $27 Million in Kinetik Holdings Stock May 4, 2026